DCAT Week '17: Novasep Opens New Bioconjugation Facility for ADCs

From DCAT Value Chain Insights (VCI)

By Patricia Van Arnum posted 04-03-2017 14:39


Kevin Daley
Director, Pharmaceuticals

Kevin Daley, Director, Pharmaceuticals, Novasep, highlighted the opening of the company’s new EUR 11 million ($11 million) bioconjugation facility, in Le Mans France, at the DCAT Member Company Announcement Forum that was held Monday March 20 at DCAT Week '17. The facility is part of Novasep’s development and manufacturing network for antibody drug conjugates (ADCs).

The 2,000-square-meter facility features two flexible GMP production suites equipped with 10 L to 400 L vessels to support both clinical and commercial manufacturing of ADCs. The stand-alone facility is purpose-built and offers R&D services, quality control, and scale-up laboratories.

Novasep has been a contract service provider in the ADC arena for more than 10 years; the new unit completes Novasep’s ADC manufacturing platform already featuring ADC payloads, drug linkers, and monoclonal antibody commercial-scale production capabilities. François D’Hooge, PhD, formerly with Spirogen, a member of the AstraZeneca group, recently joined Novasep as Head of the Bioconjugation Unit.


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription